Klajdi, our CEO at Luminary Group, will be attending the World Drug Safety Congress Europe from 09-10 October. If you'd like to grab 5-10 minutes with Klajdi to discuss potential collaborations or share insights, feel free to reach out and connect. It’s a great opportunity to explore new ideas and strengthen relationships in the industry. Luminary Group has positioned itself as a leader in the consulting space, specializing in placing top executives and offering tailored commercial, operational, and outsourcing solutions for pharmaceutical companies in niche areas such as pharmacovigilance and regulatory affairs across Europe, the USA, and APAC. We are excited to meet with our industry partners and peers at the event. Looking forward to seeing you all there! #WDSC #pharmacovigilance #pharma #regulatory #compliance #pv #lifescience #healthcare #consulting #amsterdam #netherlands #worlddrugsafetyeurope #worlddrugsafety
Luminary Group
Business Consulting and Services
Global Life Sciences Consultancy.
About us
Luminary Group is a international business consultancy focused on the life sciences and pharmaceutical sectors. Headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, we deliver comprehensive services in three key areas. Luminary Executive: Specializing in C-suite to Director-level appointments, we identify top talent for positions including Chairman, Board members, CEO, CCO, COO, AVP to Director level. Luminary Staffing: We provide both temporary and permanent staffing solutions tailored to meet the commercial, project management, medical, biometrics, software and operational needs of our clients. Luminary Consulting: Offering high-quality services in medical writing, regulatory affairs, quality assurance, pharmacovigilance, and data science for the medical and pharmaceutical industries. We also provide strategic partnerships to accelerate growth through Recruitment Process Outsourcing (RPO) and Functional Service Provider (FSP) services. Lastly, our advisory services assist in data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe, and provide guidance for business collaborations with biotechnology firms and navigating mergers and acquisitions. Our expertise includes Real World Evidence (RWE), eClinical solutions, Artificial Intelligence (AI), Biotechnology, Consulting, and Medical Devices. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from corporate giants to innovative start-ups. For more information, please visit our website: www.luminarygroup.co.uk.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
Get directions
City of London , GB
-
Get directions
4th St N, STE 300
7901
St. Petersburg, FL , 33702, US
Employees at Luminary Group
Updates
-
𝗔𝘁𝗵𝗶𝗿𝗮 𝗴𝗶𝘃𝗲𝘀 𝘂𝗽 𝗼𝗻 𝗹𝗲𝗮𝗱 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗱𝗿𝘂𝗴, 𝘀𝘄𝗶𝘁𝗰𝗵𝗲𝘀 𝘁𝗮𝗰𝗸 𝘁𝗼 𝗔𝗟𝗦 Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral candidate with the same target … https://lnkd.in/dwXgEXrf
-
𝗚𝗲𝗻𝗺𝗮𝗯 𝗰𝗵𝗼𝗽𝘀 𝗲𝗮𝗿𝗹𝘆 𝗰𝗮𝗻𝗰𝗲𝗿 𝗽𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝘀 𝘁𝗼 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗲 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝘀 Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that include an ADC from its purchase … https://lnkd.in/d-nusA6n
Genmab chops early cancer prospects to prioritize Phase 3 projects
endpts.com
-
𝗣𝗳𝗶𝘇𝗲𝗿 𝘁𝗼 𝗶𝗻𝘃𝗲𝘀𝘁 $𝟭𝗕 𝗶𝗻 𝗖𝗵𝗶𝗻𝗮 𝗼𝘃𝗲𝗿 𝗻𝗲𝘅𝘁 𝗳𝗶𝘃𝗲 𝘆𝗲𝗮𝗿𝘀 — 𝗿𝗲𝗽𝗼𝗿𝘁𝘀 Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a … https://lnkd.in/dHZmW9ft
Pfizer to invest $1B in China over next five years — reports
endpts.com
-
𝗔𝘃𝗶𝗱 𝗕𝗶𝗼𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝘁𝗼 𝗯𝗲 𝘀𝗼𝗹𝗱 𝘁𝗼 𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗲𝗾𝘂𝗶𝘁𝘆 𝗳𝗶𝗿𝗺𝘀 𝗳𝗼𝗿 $𝟭.𝟭𝗕 After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal … https://lnkd.in/dHADJWkB
Avid Bioservices to be sold to private equity firms for $1.1B
endpts.com
-
𝗡𝗲𝘄 𝗧𝗿𝘂𝗺𝗽 𝗲𝗿𝗮 𝗰𝗼𝘂𝗹𝗱 𝗯𝗲 𝗮 𝗯𝗼𝗼𝗻 𝗳𝗼𝗿 𝗯𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗠&𝗔, 𝗱𝗲𝗮𝗹𝗺𝗮𝗸𝗶𝗻𝗴 As former President Donald Trump returns to power — the The Associated Press projected his presidential victory Wednesday morning — the biopharma industry may see the door https://lnkd.in/d8tATmfN
New Trump era could be a boon for biopharma M&A, dealmaking
endpts.com
-
𝗔𝗰𝗮𝗱𝗶𝗮 𝗹𝗮𝗻𝗱𝘀 $𝟭𝟱𝟬𝗠 𝘀𝗮𝗹𝗲 𝗼𝗳 𝗿𝗮𝗿𝗲 𝗽𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗣𝗥𝗩 Acadia Pharmaceuticals Inc. has sold its priority review voucher for $150 million, the company said Tuesday, but did not disclose the buyer …Catherine Owen Adams https://lnkd.in/dYyeeruy
Acadia lands $150M sale of rare pediatric PRV
endpts.com
-
𝗖𝗲𝗿𝗲𝗯𝗿𝗮𝗹 𝘁𝗼 𝗽𝗮𝘆 𝗻𝗲𝗮𝗿𝗹𝘆 $𝟯.𝟳𝗠 𝗼𝘃𝗲𝗿 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗱 𝘀𝘂𝗯𝘀𝘁𝗮𝗻𝗰𝗲 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀 Troubled mental health startup Cerebral has agreed to pay nearly $3.7 million in connection with its efforts to encourage unauthorized prescriptions … https://lnkd.in/dGcp4HQJ
Cerebral to pay nearly $3.7M over controlled substance prescribing practices
endpts.com
-
𝗦𝗮𝗻𝗼𝗳𝗶 𝗿𝗲𝘃𝗲𝗮𝗹𝘀 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗱𝗮𝘁𝗮 𝗳𝗼𝗿 𝗕𝗧𝗞 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿 𝗳𝗿𝗼𝗺 $𝟯.𝟳𝗕 𝗣𝗿𝗶𝗻𝗰𝗶𝗽𝗶𝗮 𝘁𝗮𝗸𝗲𝗼𝘃𝗲𝗿 Sanofi's BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to … https://lnkd.in/dhXv2Ecm
Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover
endpts.com
-
𝗦𝗮𝗻𝗮 𝗻𝗮𝗿𝗿𝗼𝘄𝘀 𝗳𝗼𝗰𝘂𝘀 𝗮𝗴𝗮𝗶𝗻 𝘁𝗼 𝘇𝗲𝗿𝗼 𝗶𝗻 𝗼𝗻 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗮𝗻𝗱 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 Sana Biotechnology, Inc. is pruning its pipeline and headcount for the second time in around a year to stretch its cash and support key data readouts … https://lnkd.in/dy-vV5VB
Sana narrows focus again to zero in on diabetes and autoimmune disease
endpts.com